Renal cell cancer: Is immunotherapy dead?

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Wagstaff, J ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CYTOKINE; INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR VACCINE; VASCULOTROPIN; CANCER VACCINE; VASCULOTROPIN A;

BOLUS INJECTION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLONAL ANERGY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL TIME; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-2; KIDNEY NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36048957881     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm302     Document Type: Conference Paper

References (37)

1. Ratain MJ, Eisen T, Stadler WM et al. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2006; 24: 2505-2512.
2. Motzer RJ, Michaelson MD, Redman BJ et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
4. Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006. ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement),2006: LBA4.
5. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
6. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: 55s-57s.
7. Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncoll 1989; 7: 486-498.
8. Yang JC, Sherry RM, Steinberg SM et al. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer. J Clin Oncol 2003; 21: 3127-3132.
9. Atkins M, Regan M, McDermott D et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. Clin Cancer Res 2005; 11: 3714-3721.
10. Upton MP, Parker R, Youmans AY et al. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother 2005; 28: 488-495.
11. Small EJ, Motzer RJ. Interferon for renal cell carcinoma. In: Belldegrun A, Ritchie AWS, Figlin RA et al. (Eds). Renal and adrenal tumors. New York: Oxford University Press 2003; 381-387 Cochrane Library.
12. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10: 6302s-6303s.
13. Bukowski RM, Negrier S, Elson P. Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group. Cancer 2004; 10: 6310s-6314s.
14. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem cell transplantation. N Engl J Med 2000; 343: 750-758.
15. Artz AS, Van Besian K, Zimmerman T et al. Long-term follow-up of nonmyeloablative allogeneic stem-cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005; 35: 253-260.
16. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
17. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantaton after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
18. Blaise D, Bay JO, Faucher C et al. Reduced intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
19. Nakagawa T, Kami M, Hori A et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599-606.
20. Ueno NT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
21. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
22. Massenkeil G, Roigas J, Nagy M et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: Delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004; 34: 309-316.
23. Tykodi SS, Warren EH, Thompson JA et al. Allogeneic hematopoietic cell transplantaton for metastatic renal cell carcinoma after nonmyeloablative conditioning: Toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-7811.
24. Rini BI, Halabi S, Barrier R et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB Intergroup phase II study. Biol Blood Marrow Transplant 2006; 12: 778-785.
25. Barkholt L, Bregni M, Remberger M et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17: 1134-1140.
26. Yang JC, Childs R. Immunotherapy for Renal Cell Cancer. J Clin Oncol 2006; 24: 5576-5583.
27. Dirkx AE, oude Egbrink MG, Castermans K et al. Ant-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20: 621-630.
28. Dirkx AEM, oude Egbrink MGA, Kuijpers MJE et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression: A tumor size dependent effect. Cancer Res 2003; 63: 2322-2329.
29. Dillman RO, Barth NM, VanderMolen LA et al. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm 2001; 16: 47-54.
30. Dillman RO, Wiemann M, Nayak SK et al. Interferon-gamma or granulocyte-macrophage colony stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase 2 trial of the cancer biotherapy research group. J Immunother 2003; 26: 367-373.
31. Nelson WG, Simons JW, Mikhak B et al. Cancer cells engineered to secrete granulocyte macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46: S67-S72.
32. Holt L, Ramoner R, Zelle-Rieser C et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54: 663-670.
33. Gibitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003; 26: 412-419.
34. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63: 2127-2133.
35. Marten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase VII trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14: 483-494.
36. Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51: 637-644.
37. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699-4708.